Congenital heart diseaseSeeking Optimal Relation Between Oxygen Saturation and Hemoglobin Concentration in Adults With Cyanosis from Congenital Heart Disease
Section snippets
Methods
We prospectively enrolled consecutive adults with congenital heart disease in a descriptive cross-sectional study. Patients gave consent, and institutional ethics review approved the protocol. Patients were included if they had a known congenital defect with a right-to-left shunt. We included patients with a wide range of O2sat, including some patients who had undergone previous repair and had a normal O2sat at the study. All tests were obtained within a 24-hour period. Other data from the
Results
A total of 65 patients were studied (mean age 36 ± 12 years, 67% women). For the whole group, the O2sat at rest was 81 ± 8%, hemoglobin was 19.6 ± 2.9 g/dl, and hematocrit was 60 ± 8%. The anatomic diagnoses are listed in Table 2, as well as their group designation. All but 1 patient had pulmonary vascular disease. Of the 65 patients, 20 had likely been cyanotic at birth, with 45 (largely with simple shunts) having developed right to left shunting over time. No patient was found to have
Discussion
The concept of determining an ideal set point for erythropoiesis in congenital heart disease with cyanosis is not new. An “optimal hematocrit” between oxygen delivery and hyperviscosity was studied decades ago,4 although limited by the use of ex vivo models.5 Few clinical studies have addressed this relation and largely only in children or adolescents.5, 6 A linear relation has been shown, although less steep than ours.5, 7, 8 A right shift of the oxyhemoglobin dissociation curve has been seen
References (13)
- et al.
Blood viscosity and its relation to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease
J Am Coll Cardiol
(2006) - et al.
Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity
J Am Coll Cardiol
(2007) - et al.
Serum erythropoietin levels in patients with congenital heart disease
J Pediatr
(1987) - et al.
Erythropoietin in cyanotic heart disease
Am Heart J
(1988) - et al.
Effect of iron deficiency on tissue oxygen delivery in cyanotic congenital heart disease
Am J Cardiol
(1988) - et al.
Chronic hypoxaemia and decompensated erythrocytosis in cyanotic congenital heart disease
Lancet
(1986)
Cited by (48)
Failing with Cyanosis-Heart Failure in End-Stage Unrepaired or Partially Palliated Congenital Heart Disease
2024, Heart Failure ClinicsEisenmenger Syndrome: JACC State-of-the-Art Review
2022, Journal of the American College of CardiologyRed blood cell distribution width in addition to N-terminal prohormone of B-type natriuretic peptide concentration improves assessment of risk of cardiovascular events in adult patients with congenital heart disease
2020, Archives of Cardiovascular DiseasesCitation Excerpt :Although a number of studies in the general population [1,2] and in patients with coronary artery disease [3], heart failure [4,5], pulmonary arterial hypertension [6] and congenital heart disease (CHD) [7,8] have linked high RDW values with a worse prognosis, there are confounding factors, such as renal failure, anaemia and cyanosis, which form part of the causal pathway of anisocytosis that may obscure the real effect of RDW on outcome. In fact, RDW plays an essential role in the differential diagnosis of anaemia [9,10], being an economic tool for detecting low serum apoferritin concentrations in patients with CHD who are cyanotic [11] – a population with a high percentage of anaemia despite optimizing their haemoglobin concentrations [12]. Therefore, RDW may be an epiphenomenon rather than an effective player in the pathogenesis of cardiovascular diseases [13].
Hematologic changes in cyanotic congenital heart disease: a review
2020, Progress in Pediatric CardiologyEisenmenger Syndrome: A Multisystem Disorder—Do Not Destabilize the Balanced but Fragile Physiology
2019, Canadian Journal of Cardiology
The study was funded by the Clinical Research Committee, Royal Brompton Hospital. Dr. Broberg has received support from the Waring Trust (London, United Kingdom) through the Royal Brompton Hospital and the Tartar Trust (Portland, Oregon) through the Oregon Health and Sciences University. Dr. Gatzoulis and the Royal Brompton Adult Congenital Heart Centre have received support from the British Heart Foundation, London, United Kingdom and unrestricted research funds from Actelion UK (London, United Kingdom).